Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer-Specific Mortality

作者：Pomerantz Mark M; Werner Lillian; Xie Wanling; Regan Meredith M; Lee Gwo Shu Mary; Sun Tong; Evan Carolyn; Petrozziello Gillian; Nakabayashi Mari; Oh William K; Kantoff Philip W; Freedman Matthew L^*

来源：Cancer Prevention Research, 2011, 4(5): 719-728.

DOI：10.1158/1940-6207.CAPR-10-0292

Genome-wide association studies have detected more than 30 inherited prostate cancer risk variants. While clearly associated with risk, their relationship with clinical outcome, particularly prostate cancer-specific mortality, is less well known. We investigated whether the risk variants are associated with various measures of disease aggressiveness and prostate cancer-specific mortality. In a cohort of 3,945 men of European ancestry with prostate cancer, we genotyped 36 single nucleotide polymorphisms (SNP): 35 known prostate cancer risk variants and one SNP (rs4054823) that was recently reported to be associated with prostate cancer aggressiveness. The majority of subjects had a diagnosis of prostate cancer between 1995 and 2004, and the cohort included a total of 580 prostate cancer-specific deaths. We evaluated associations between the 36 polymorphisms and prostate cancer survival, as well as other clinical parameters including age at diagnosis, prostate-specific antigen (PSA) at diagnosis, and Gleason score. Two SNPs, rs2735839 at chromosome 19(413 and rs7679673 at 4q24, were associated with prostate cancer-specific survival (P = 7 x 10(-4) and 0,014, respectively). A total of 12 SNPs were associated with other variables (P < 0.05): age at diagnosis, PSA at diagnosis, Gleason score, and/or disease aggressiveness based on D'Amico criteria, Genotype status at rs4054823 was not associated with aggressiveness or outcome. Our results identify two common polymorphisms associated with prostate cancer-specific mortality. Cancer Prey Res; 4(5); 719-28.

• 出版日期2011-5